Clinical Trials · NCT02789878
Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Instituto do Cancer do Estado de São Paulo
- Enrollment
- 64
- Start date
- Jan 2019
- Locations
- 1 site, Brazil
- Primary endpoint
- Pathologic response